Molecular structure of Bromocriptine mesylate, CAS Number: 22260-51-1
Bromocriptine mesylate (CAS 22260-51-1)
See product citations (4)
Alternate Names:
Parlodel; Cycloset
Application:
Bromocriptine mesylate is a selective D2 and D3 dopamine receptor agonist and NOS1 inhibitor
CAS Number:
22260-51-1
Purity:
≥98%
Molecular Weight:
750.70
Molecular Formula:
C32H40BrN5O5•CH3SO3H
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Bromocriptine mesylate is the mesylate salt of Bromocriptine, an ergoline-derived selective agonist of D2DR and D3DR (D2 and D3 dopamine receptors). Bromocriptine demonstrated a ten-fold higher affinity at D2 over D3 in recombinant dopamine receptors. When Bromocriptine is combined with the D1-selective dopamine receptor agonist SKF38393, normalization of hyperphagia and resultant reductions of body weight and fat, serum glucose, free fatty acid and triglyceride concentrations is reported in agonist-administered ob/ob mice. Bromocriptine mesylate is an inhibitor of NOS1.
Bromocriptine mesylate (CAS 22260-51-1) References
- Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors. | Perachon, S., et al. 1999. Eur J Pharmacol. 366: 293-300. PMID: 10082211
- Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists. | Scislowski, PW., et al. 1999. Int J Obes Relat Metab Disord. 23: 425-31. PMID: 10340822
- Bromocriptine/SKF38393 treatment ameliorates dyslipidemia in ob/ob mice. | Zhang, Y., et al. 1999. Metabolism. 48: 1033-40. PMID: 10459570
- Treatment of Khat Addiction with Bromocriptine Mesylate: A Case Report and Review of Cocaine- and Amphetamine-Like Effects. | Giannini, AJ. and Nakoneczie, AM. 1995. Am J Ther. 2: 487-489. PMID: 11850696
- Bromocriptine: old drug, new formulation and new indication. | Holt, RI., et al. 2010. Diabetes Obes Metab. 12: 1048-57. PMID: 20977575
- Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus. | Kerr, JL., et al. 2010. Ann Pharmacother. 44: 1777-85. PMID: 20978217
- Effect of bromocriptine on cardiovascular complications associated with metabolic syndrome in fructose fed rats. | Nade, VS., et al. 2012. Indian J Pharmacol. 44: 688-93. PMID: 23248395
- Bromocriptine mesylate (Cycloset) for type 2 diabetes mellitus. | Weiland, CM. and Hilaire, ML. 2013. Am Fam Physician. 87: 718-20. PMID: 23939451
- Bromocriptine mesylate for lactation suppression: a risk for postpartum hypertension? | Watson, DL., et al. 1989. Obstet Gynecol. 74: 573-6. PMID: 2797633
- THE RESTORATION OF HYPOTHALAMIC SIGNALING SYSTEMS AS ONE OF THE CAUSES TO IMPROVE THE METABOLIC PARAMETERS IN BROMOCRYPTINE-TREATED RATS WITH NEONATAL MODEL OF DIABETES MELLITUS. | Derkach, KV., et al. 2017. Tsitologiia. 59: 140-7. PMID: 30199162
- Bromocriptine mesylate improves glucose tolerance and disposal in a high-fat-fed canine model. | Moore, MC., et al. 2020. Am J Physiol Endocrinol Metab. 319: E133-E145. PMID: 32459527
- The therapeutic effect of bromocriptine as mesylate and estradiol valerate on serum and blood biochemistry of common quails. | Ul-Abideen, Z., et al. 2022. Poult Sci. 101: 101552. PMID: 34942520
- The combined intervention of therapy and bromocriptine mesylate to improve functional performance after brain injury. | Pulaski, KH. and Emmett, L. 1994. Am J Occup Ther. 48: 263-70. PMID: 8178923
Inhibitor of:
NOS, and NOS1.Activator of:
D2DR, and D3DR.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Bromocriptine mesylate, 100 mg | sc-200395 | 100 mg | $98.00 | |||
Bromocriptine mesylate, 500 mg | sc-200395A | 500 mg | $362.00 | |||
Bromocriptine mesylate, 1 g | sc-200395B | 1 g | $540.00 |